Investigational Drug Information for TVB-2640
✉ Email this page to a colleague
What is the drug development status for TVB-2640?
TVB-2640 is an investigational drug.
There have been 12 clinical trials for TVB-2640.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 18th 2021.
The most common disease conditions in clinical trials are Liver Diseases, Fatty Liver, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Sagimet Biosciences Inc., Ascletis Pharmaceuticals Co., Ltd., and 3V Biosciences, Inc.
There is one US patent protecting this investigational drug and one hundred and eight international patents.
Summary for TVB-2640
| US Patents | 1 |
| International Patents | 108 |
| US Patent Applications | 28 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 2 (2021-11-18) |
| Vendors | 32 |
Recent Clinical Trials for TVB-2640
| Title | Sponsor | Phase |
|---|---|---|
| A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function | Sagimet Biosciences Inc. | Phase 1 |
| Phase I Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer | Sagimet Biosciences Inc. | Phase 1 |
| Phase I Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer | Weill Medical College of Cornell University | Phase 1 |
Clinical Trial Summary for TVB-2640
Top disease conditions for TVB-2640
Top clinical trial sponsors for TVB-2640
US Patents for TVB-2640
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TVB-2640 | ⤷ Try a Trial | Heterocyclic modulators of lipid synthesis | 3-V Biosciences, Inc. (Menlo Park, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TVB-2640
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TVB-2640 | Canada | CA2979696 | 2035-03-19 | ⤷ Try a Trial |
| TVB-2640 | China | CN107428728 | 2035-03-19 | ⤷ Try a Trial |
| TVB-2640 | European Patent Office | EP3277675 | 2035-03-19 | ⤷ Try a Trial |
| TVB-2640 | Spain | ES2910049 | 2035-03-19 | ⤷ Try a Trial |
| TVB-2640 | Japan | JP2018508547 | 2035-03-19 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
